Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights

On July 30, 2020 Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, reported that it plans to host a conference call on Thursday, August 06, 2020, at 8:30 a.m. Eastern Time to discuss its financial results for the second quarter and recent operational highlights (Press release, Selecta Biosciences, JUL 30, 2020, https://selectabio.gcs-web.com/news-releases/news-release-details/selecta-biosciences-host-conference-call-and-webcast-discuss-1 [SID1234562582]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10138605. Investors and the public can access the live and archived webcast of this call via the Investors & Media section of the company’s website, www.selectabio.com.

Gan & Lee Pharmaceuticals Initiates First-in Human Phase 1 Clinical Trial for New Anti-tumor Drug GLR2007

On July 30, 2020 Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), reported that with the initiation of our first-in-human Phase 1 clinical trial for GLR2007, our internally-invented, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor as a potential therapy for advanced solid tumors (Press release, Gan and Lee Pharmaceuticals, JUL 30, 2020, View Source;lee-pharmaceuticals-initiates-first-in-human-phase-1-clinical-trial-for-new-anti-tumor-drug-glr2007-301103340.html [SID1234562599]). CDK4/6 activity is central to cell cycle regulation and has a key role in the occurrence and progression of a variety of cancers.1 2 Therefore, Gan & Lee views CDK4/6 as an attractive therapeutic target agent. This Phase 1 clinical trial is a multicenter, open- label, study designed to establish the safety, tolerability, and optimal dosing strategy of GLR2007 in patients with advanced solid tumors. Dr. Lawrence Hill, CEO, Gan & Lee US says, "Based on encouraging pre-clinical data and the high unmet need, 3 GLR2007 is a promising new investigational compound that could potentially address unmet medical need for patients with advanced solid tumors. We are excited to begin this Phase 1 clinical study (NCT04444427) and look forward to collaborating with patients, caregivers and the medical community to make a meaningful difference to people living with cancer."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Brazilian National Institute of Industrial Property Grants AskAt’s EP4 Antagonist Cancer Use Patent

On July 29, 2020 AskAt Inc. (AskAt) received a notice of allowance dated July 21, 2020 from the Brazilian National Institute of Industrial Property (NIIP) in connection with Application No. PI1014174-0, a use patent for AskAt’s EP4 antagonists in the treatment of epithelial cancers (Press release, AskAt, JUL 29, 2020, View Source [SID1234562479]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clinical Development of Grapiprant for Cancer Immunotherapy Ikena Oncology (formally Kyn Therapeutics, a parent company of Arrys Therapeutics, which licensed worldwide rights to AskAt’s EP4 antagonists except in China) and Ningbo NewBay Pharmaceutical Co. Ltd. (a subsidiary of Ningbo Tai Kang Medical Technology Co. Ltd., which licensed AskAt’s EP4 antagonists for cancer use in China), are currently conducting clinical studies of grapiprant (IK-007/RMX1002) in the U.S. and China, respectively.

STAND UP TO CANCER AWARDS $1.1 MILLION IN GRANTS TO RESEARCH TEAMS

On July 29, 2020 Stand Up To Cancer reported five new awards that will cut across institutional and national lines to foster collaborative research and explore new paths to improve cancer treatment (Press release, SU2C, JUL 29, 2020, View Source [SID1234562505]). The projects will receive a combined total of $1.1 million in funding to address some of the most pressing questions associated with colorectal, Ewing sarcoma, pancreatic, lung and pediatric cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Named for Nobel laureate Phillip A. Sharp, PhD, chairperson of Stand Up To Cancer’s Scientific Advisory Committee, the Phillip A. Sharp Innovation in Collaboration Awards focus on bringing new perspectives together to benefit cancer research. Sharp is an Institute professor at David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology.

"What sets Stand Up To Cancer apart is its ability to break down historically restrictive silos that cancer researchers have typically worked in," said Sharp. "These grants allow us to further emphasize the importance of collaboration among researchers across different institutions and specialties so that we can bring together the resources and brainpower needed to address some of the biggest challenges we face in cancer research and treatment today."

The Sharp Awards are unique in their collaborative format, but also in the simple and quick selection process. The grants were selected at the annual Stand Up To Cancer Scientific Summit in January 2020 and were based on a 250-word outline of the idea that was reviewed by a board of experts at the summit. Each winning proposal submits a more detailed application before the grant is confirmed. Leaders of each team must be from different existing Stand Up To Cancer research teams. The program, now in its seventh year, encourages the inclusion of early-career investigators.

"The unique nature of the Sharp Awards allows for the extraordinary talent across the SU2C community to come together from different teams and individual grants to tackle some of the toughest new questions facing cancer research," said William G. Nelson, MD, PhD, vice chair of the Stand Up To Cancer Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center Johns Hopkins. "These new grants will help to build upon existing research, while creating the opportunity for researchers to work together on new and innovative projects."

The American Association for Cancer Research (AACR) (Free AACR Whitepaper), Stand Up To Cancer’s scientific partner, will support the administration of these projects receiving funding for the 2020 Sharp Awards, including:

Florencia McAllister, MD, University of Texas MD Anderson Cancer Center, early career investigator on the SU2C-Lustgarten Foundation Pancreatic Cancer Interception Dream Team, and Luis A. Diaz Jr., MD, Memorial Sloan Kettering Cancer Center, leader of the SU2C Colorectal Cancer Dream Team. This team will conduct research on "Genomic and therapeutic implications of selective bacterial and fungal colonization of gastrointestinal malignancies." Total funding: $200,000.
William Freed-Pastor, MD, PhD, Massachusetts Institute of Technology and Dana-Farber Cancer Institute, early career investigator on the SU2C-Lustgarten Foundation Pancreatic Cancer Interception Dream Team, and Phil Greenberg, MD, Fred Hutchinson Cancer Research Center, formerly principal investigator on the SU2C–Cancer Research Institute Cancer Immunology Dream Team, currently serving as SU2C Scientific Reviewer. This team will conduct research on "Utilizing tumor organoids to facilitate the development of effective strategies to target pancreatic cancer with engineered T cells." Total funding: $200,000.
Karin Pelka, PhD, Broad Institute of Massachusetts Institute of Technology and Harvard, SU2C Peggy Prescott Early Career Scientist and Matthew Hellmann, MD, Memorial Sloan Kettering Cancer Center, early career investigator on the SU2C–American Cancer Society Lung Cancer Dream Team and co-leader of the SU2C Catalyst Lung Immuno-Epigenetics Team. This team will conduct research on "Can scRNAseq-derived gene programs predict anti-PD1 response in high TMB CRC and NSCLC patients?" Total funding: $200,000.
Michal Sheffer, PhD, Dana Farber Cancer Institute, post-doctoral Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) fellow, SU2C Natural Killer Cell Resistance Convergence Research Team and David Kirsch, MD, PhD, Duke University, leader of the SU2C Catalyst Sarcoma Research Team. This team will conduct research on "Harnessing NK Cells to Treat Pediatric Cancers." This grant was funded with support from the Emily Whitehead Foundation. Total funding: $250,000.
Poul Sorensen, MD, PhD, University of British Columbia, principal investigator on the SU2C Canada Metastatic Breast Cancer Dream Team and the St. Baldrick’s Foundation – SU2C Pediatric Cancer Dream Team, and Elizabeth Lawlor, MD, PhD, Seattle Children’s Research Institute, principal investigator, Pediatric SU2C Catalyst Epigenetics Research Team, and 2009 SU2C Innovative Research Grant recipient. This team will conduct research on "Enhancing ferroptosis to block Ewing sarcoma metastatic capacity." This grant was funded with support from the Kate McGarrigle Fund and the Steve Golin Prize. Total funding: $250,000.
Special awards this year were funded by the Emily Whitehead Foundation, the Kate McGarrigle Fund, and the Steve Golin Prize.

The Emily Whitehead Foundation is named after the first pediatric patient to receive CAR-T therapy for leukemia. These special awards focus specifically on addressing various therapeutic areas in pediatric cancer research. "We are honored to continue our collaboration with SU2C to fund these researchers focused on furthering pediatric cancer immunotherapy treatments," said Tom Whitehead, co-founder of the Emily Whitehead Foundation. "Collaborative research is essential to developing new, successful treatments. Our hope is that by funding these research grants we will be able to give more kids the chance to survive their cancer and lead happy, healthy lives."

The SU2C Kate McGarrigle Fund is a collaboration of Stand Up To Cancer and singers Rufus Wainwright and Martha Wainwright that raises much-needed funds for sarcoma research and provides music resources to cancer patients and survivors with a passion for music through the Music As Healing program. Kate McGarrigle, Canadian singer, songwriter, mother of Rufus Wainwright and Martha Wainwright, died of sarcoma in 2010.

The Steve Golin Fund accelerates research in Ewing sarcoma, in memory of Steve Golin, the American film producer who died of Ewing sarcoma in 2019. Ewing sarcoma is a rare bone and soft tissue cancer predominantly found in children.

Akoya Biosciences Collaborates with Leading Cancer Center to Discover Predictive Biomarkers for Cancer

On July 29, 2020 Akoya Biosciences, Inc., The Spatial Biology Company, reported a collaboration with UCSF Helen Diller Family Comprehensive Cancer Center (Press release, Akoya Biosciences, JUL 29, 2020, View Source [SID1234562522]). Scientists at UCSF Helen Diller Family Comprehensive Cancer Center have chosen Akoya’s Phenoptics multiplex immunofluorescence platform for developing predictive and prognostic biomarkers, particularly for use in selecting the most effective neoadjuvant and adjuvant immunotherapies for patients with early breast cancer. Click here to view a multimedia version of the press release, including media-ready images, downloadable resources, and more.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At UCSF, this collaboration will be led by Michael Campbell, PhD, and Laura Esserman, MD, MBA. Dr. Campbell is an immunologist who has worked in partnership with Dr. Esserman to better understand how to optimize immunotherapy. He is driving the work on the Phenoptics platform to develop predictors of response to the immuno-oncology drug combinations, and to use these insights to develop more effective combinations. Together they are working both on high risk invasive breast cancer and high-risk ductal carcinoma in situ (DCIS).

Dr. Esserman is a professor in the departments of Surgery and Radiology who co-leads the breast oncology program at the UCSF Helen Diller Family Comprehensive Cancer Center, and is the Principal Investigator of the I-SPY Trials, sponsored by the Quantum Leap Healthcare Collaborative. Following extensive evaluation of biomarker testing methods, Dr. Esserman and her team have standardized biomarker discovery and development efforts on the Phenoptics platform to measure as many as six markers at a time on a single pathology slide using multiplex immunofluorescence. The Phenoptics platform is the chosen platform for the I-SPY Trials.

"There is a clear need for biomarkers to guide both the choice and assessment of immune targeted combinations for high risk early-stage cancers, where opportunities for cure are much greater," said Dr. Esserman. "We believe that multiplexed immunofluorescence will lead to robust, predictive assays, because it enables better understanding of the cell-level biology underlying disease progression and response to therapy, by revealing the spatial arrangements and interactions of cells in the tumor microenvironment."

Immunotherapies harness the immune system to fight cancer and are increasingly being used in the early high-risk setting. The partnership’s goals are to make these therapies more effective and to understand the immune response, key to making them work for more patients. There is an urgent need for biomarkers that more accurately predict which patients will respond to a particular therapy. Multiplex immunofluorescence preserves critical spatial data about cell proximity and interaction in the tumor microenvironment, with the potential to provide higher predictive power compared to other biomarker approaches. Akoya’s Phenoptics platform provides an end-to-end solution for discovery research and clinical trials with the reproducibility, sensitivity and throughput needed to develop new biomarkers and has become the standard for biomarker-based clinical trials and translational research.

Cliff Hoyt, Vice President of Translational and Scientific Affairs at Akoya, commented: "Dr. Esserman is well known for her substantial achievements in characterizing the tumor microenvironment and treating breast cancers and it is an honor for our team to collaborate with her lab. With Dr. Esserman’s focus on practical and effective steps to improve drug development and the standard of care, we believe that this collaboration will have a real impact on patient treatment in the coming years."